Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer.

The Journal of clinical investigation - 15 Aug 2023

Nardi Francesca, Perurena Naiara, Schade Amy E, Li Ze-Hua, Ngo Kenneth, Ivanova Elena V, Saldanha Aisha, Li Chendi, Gokhale Prafulla C, Hata Aaron N, Barbie David A, Paweletz Cloud P, Jänne Pasi A, Cichowski Karen

Abstract excerpt

Despite the success of KRAS G12C inhibitors in non-small cell lung cancer (NSCLC), more effective treatments are needed. One preclinical strategy has been to cotarget RAS and mTOR pathways; however, toxicity due to broad mTOR inhibition has limited its utility. Therefore, we sought to develop a more refined means of targeting cap-dependent translation and identifying the most therapeutically important eukaryotic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-bcl-2

Share to Proto-Oncogene Proteins p21(ras)

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 37384411
DOI: 10.1172/JCI167651
PMCID: PMC10425214

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer.PMID 37384411Read ↗

KRASG12C Can Either Promote or Impair Cap-Dependent Translation in Two Different Lung Adenocarcinoma Cell Lines.Semantic proximity Read ↗

Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.Semantic proximity Read ↗

Bi-steric mTORC1-selective Inhibitors activate 4EBP1 reversing MYC-induced tumorigenesis and synergize with immunotherapySemantic proximity Read ↗

Inhibition of ULK1/2 and KRAS <sup>G12C</sup> controls tumor growth in preclinical models of lung cancerSemantic proximity Read ↗

Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.Semantic proximity Read ↗

CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A.Semantic proximity Read ↗

Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers.Semantic proximity Read ↗

STAT1 Promotes KRAS Colon Tumor Growth and Susceptibility to Pharmacological Inhibition of Translation Initiation Factor eIF4ASemantic proximity Read ↗

Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.Semantic proximity Read ↗

Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphomaSemantic proximity Read ↗

Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer TherapySemantic proximity Read ↗

Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.